BAP1 and neoplasm: Loss of BAP1 has been described as a candidate predictive marker of immunotherapy response in MPM [76] and in peritoneal mesothelioma BAP1 loss has been linked to an inflammatory tumour microenvironment with increased T cell infiltrate [63].